Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GH NYSE:HIMS NASDAQ:NTRA NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHGuardant Health$50.82+2.6%$45.51$20.14▼$53.42$6.14B1.442.17 million shs2.29 million shsHIMSHims & Hers Health$48.96+1.1%$52.90$13.47▼$72.98$10.84B2.0223.59 million shs30.53 million shsNTRANatera$158.48-0.1%$160.52$92.14▼$183.00$21.67B1.731.42 million shs1.06 million shsVCYTVeracyte$26.58+0.9%$27.90$19.73▼$47.32$2.06B2.07917,309 shs739,796 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHGuardant Health-1.41%-4.80%+3.08%+24.44%+72.31%HIMSHims & Hers Health+0.89%-3.20%-14.35%+85.77%+132.63%NTRANatera-1.74%-6.07%-3.10%+20.01%+40.76%VCYTVeracyte-4.25%-2.55%-4.08%-8.80%+22.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGHGuardant Health3.8226 of 5 stars2.51.00.04.43.82.50.6HIMSHims & Hers Health2.162 of 5 stars2.02.00.00.01.83.31.9NTRANatera2.0882 of 5 stars2.52.00.00.03.32.50.6VCYTVeracyte3.76 of 5 stars3.41.00.04.33.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHGuardant Health 3.00Buy$53.765.79% UpsideHIMSHims & Hers Health 1.92Reduce$39.58-19.15% DownsideNTRANatera 3.00Buy$184.6316.50% UpsideVCYTVeracyte 2.70Moderate Buy$40.9053.88% UpsideCurrent Analyst Ratings BreakdownLatest GH, VCYT, NTRA, and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025HIMSHims & Hers HealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$45.006/23/2025HIMSHims & Hers HealthCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell6/23/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$30.006/23/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform6/23/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold6/13/2025GHGuardant HealthMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.006/11/2025HIMSHims & Hers HealthMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$40.006/4/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$61.00 ➝ $65.005/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHGuardant Health$739.02M8.52N/AN/A($1.13) per share-44.97HIMSHims & Hers Health$1.48B7.42$0.36 per share137.49$2.16 per share22.67NTRANatera$1.70B12.75N/AN/A$9.05 per share17.51VCYTVeracyte$445.76M4.67$1.05 per share25.40$15.17 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHGuardant Health-$436.37M-$3.39N/AN/AN/A-53.82%N/A-26.77%8/6/2025 (Estimated)HIMSHims & Hers Health$126.04M$0.6970.9694.151.789.24%22.75%15.51%8/4/2025 (Estimated)NTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)VCYTVeracyte$24.14M$0.4164.8336.92N/A7.13%6.14%5.60%8/5/2025 (Estimated)Latest GH, VCYT, NTRA, and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025VCYTVeracyte$0.31N/AN/AN/A$120.90 millionN/A8/4/2025Q2 2025HIMSHims & Hers Health$0.17N/AN/AN/A$550.06 millionN/A5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million5/5/2025Q1 2025HIMSHims & Hers Health$0.12$0.20+$0.08$0.20$535.21 million$586.01 million4/30/2025Q1 2025GHGuardant Health-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHGuardant HealthN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHGuardant HealthN/A4.113.76HIMSHims & Hers HealthN/A1.591.32NTRANateraN/A3.873.74VCYTVeracyteN/A5.104.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHGuardant Health92.60%HIMSHims & Hers Health63.52%NTRANatera99.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipGHGuardant Health6.10%HIMSHims & Hers Health17.71%NTRANatera7.60%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHGuardant Health2,021123.89 million116.33 millionNot OptionableHIMSHims & Hers Health1,637223.83 million184.19 millionOptionableNTRANatera4,434136.55 million126.17 millionOptionableVCYTVeracyte79078.32 million77.22 millionOptionableGH, VCYT, NTRA, and HIMS HeadlinesRecent News About These CompaniesWealth Enhancement Advisory Services LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT)July 6 at 3:14 AM | marketbeat.comVeracyte, Inc. (VCYT) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Sumitomo Mitsui Trust Group Inc.July 1, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Downgraded by Wall Street Zen to "Hold"June 29, 2025 | americanbankingnews.comWall Street Zen Downgrades Veracyte (NASDAQ:VCYT) to HoldJune 28, 2025 | marketbeat.comAMI Asset Management Corp Has $1.44 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)June 26, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from AnalystsJune 23, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last yearJune 20, 2025 | finance.yahoo.comGAMMA Investing LLC Purchases 18,840 Shares of Veracyte, Inc. (NASDAQ:VCYT)June 19, 2025 | marketbeat.comCathie Wood’s ARK buys BWX stock, sells Adaptive BiotechJune 18, 2025 | investing.comExchange Traded Concepts LLC Increases Stake in Veracyte, Inc. (NASDAQ:VCYT)June 17, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Assenagon Asset Management S.A.June 14, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Stock Rating Upgraded by Wall Street ZenJune 14, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Shares Down 4.8% - Should You Sell?June 12, 2025 | marketbeat.comVeracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved ProfitabilityJune 9, 2025 | msn.comCathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D SystemsJune 7, 2025 | benzinga.comInsider Selling: John Leite Sells Shares of Veracyte Inc (VCYT)June 6, 2025 | gurufocus.comVeracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?June 6, 2025 | msn.comCathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and GuardantJune 4, 2025 | investing.comVeracyte (VCYT) Shares Pulled Back Despite Beating ExpectationsJune 3, 2025 | msn.comVeracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCOMay 28, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeWhy Goldman Sachs Suddenly Boosted These 3 Trucking StocksBy Gabriel Osorio-Mazilli | June 9, 2025View Why Goldman Sachs Suddenly Boosted These 3 Trucking StocksApplied Digital: Now the High-Stakes Race to Build BeginsBy Jeffrey Neal Johnson | June 17, 2025View Applied Digital: Now the High-Stakes Race to Build Begins3 Stocks With Near-Unanimous Buys That Could Rally HigherBy Nathan Reiff | July 2, 2025View 3 Stocks With Near-Unanimous Buys That Could Rally HigherGH, VCYT, NTRA, and HIMS Company DescriptionsGuardant Health NASDAQ:GH$50.82 +1.28 (+2.58%) Closing price 04:00 PM EasternExtended Trading$50.82 +0.01 (+0.01%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Hims & Hers Health NYSE:HIMS$48.96 +0.54 (+1.12%) Closing price 03:59 PM EasternExtended Trading$48.95 -0.01 (-0.02%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Natera NASDAQ:NTRA$158.48 -0.21 (-0.13%) Closing price 04:00 PM EasternExtended Trading$159.07 +0.59 (+0.37%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Veracyte NASDAQ:VCYT$26.58 +0.24 (+0.91%) Closing price 04:00 PM EasternExtended Trading$26.79 +0.21 (+0.79%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
